Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors

NCT01885195 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01885195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01885195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
October 10, 2013
Completion date
April 11, 2017
Enrollment
110 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor and hematologic malignancies